Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.
about
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialLymphoma Immunotherapy: Current StatusPharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cellsNovel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystemPredictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Clonal relationships in recurrent B-cell lymphomasMonotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Antibody therapy for pediatric leukemia.Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma.Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.Long-term follow-up of patients with relapsed or refractory non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.
P2860
Q26747753-9B6E9FDC-F075-4986-AC40-61221302AD21Q26782902-7572A919-A97E-4A2D-8B5C-CF0DE60006B7Q35672293-9F830068-8AD0-46BD-805D-3B2B247EFB28Q36052352-C82DE1EF-3269-482D-9DB6-F47A248467CBQ36581182-5F89C4B8-B276-46B2-B38F-C28C844710C2Q36744857-D30298E1-D922-4FC1-A254-2E859BC9E994Q37022176-4C2BF2DF-6B73-4572-93CD-B8C022E2C567Q37357478-4AE086AA-7C72-4C61-8296-9F86B257201FQ37363925-BB626A73-EC5C-49D4-859B-0EE86F7DC678Q37672472-A7C4F7FF-25A4-4E67-AF12-1C6044AAB72EQ37725578-F7B64AC8-8A2C-4CA8-B97D-10224D5A4FA0Q38581826-B3F13B8B-92DE-4FA5-AA84-71202D7A3137Q38878964-07B246E7-66C5-491E-9FF2-7F3B2F4009CCQ38912282-6A45E1F0-B338-4E46-9E57-3EA52094B8BDQ40303819-23D71087-C9C9-4909-AE9D-899CBFF95228Q47169310-D5BA9C82-511E-43AF-BB3B-C79C5CA08445Q47898168-31F2749E-63D6-4484-9A00-A128B9B0DEC0Q51089670-38918D43-5F87-4629-9B45-807FB7D7AA6BQ52372502-FD1A99AD-87A1-4399-A80A-5DEF750AEC10Q52562955-F9FF5201-7E70-4205-B687-97DABC103449Q53769050-20A6F120-E865-4086-893A-002C9829623C
P2860
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment challenges in the ma ...... novel and emerging therapies.
@en
Treatment challenges in the ma ...... novel and emerging therapies.
@nl
type
label
Treatment challenges in the ma ...... novel and emerging therapies.
@en
Treatment challenges in the ma ...... novel and emerging therapies.
@nl
prefLabel
Treatment challenges in the ma ...... novel and emerging therapies.
@en
Treatment challenges in the ma ...... novel and emerging therapies.
@nl
P2860
P356
P1476
Treatment challenges in the ma ...... novel and emerging therapies.
@en
P2093
Mark P Chao
P2860
P304
P356
10.2147/CMAR.S34273
P407
P577
2013-08-23T00:00:00Z